Clinical trials: Psoriasis Vulgaris
Psoriasis
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks.
- Trial name
- NCT00279162
- Testing
- Calcipotriene/betamethasone gel and ointment
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- LEO Pharma
Psoriasis With Cell-derived Microparticles
The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)
Background: Psoriasis, a common inflammatory disease, is associated with atherosclerotic vascular diseases, including stroke, myocardial infarction, and impaired microcirculations, among which circulating microparticles play an…
- Trial name
- NCT02693470
- Testing
- Ustekinumab
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Psoriasis Vulgaris
Use of Botulinum Toxin to Treat Psoriasis
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis.
- Trial name
- NCT00816517
- Testing
- injection of botulinum toxin type A.
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Plaque Psoriasis
Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment.
- Trial name
- NCT01710046
- Testing
- (CP-6890,550) Tofacitinib, (CP-690,550) Tofacitinib
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Vitiligo Vulgaris, Psoriasis
PALLAS Laser for Skin Diseases
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
- Conditions
- Vitiligo Vulgaris, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- PALLAS-UV (NCT07250997)
- Testing
- UVB laser treatment
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Psoriasis Vulgaris, Psoriasis
Modified Intermittent Fasting in Psoriasis
The complexity of psoriasis is partially affected by dietary effects, and some diets have shown to be beneficial in psoriasis. Intermittent fasting has been shown to improve many of these disturbances, even inflammatory…
- Trial name
- MANGO (NCT04418791)
- Testing
- Modified Intermittent Fasting followed by Regular Diet, Regular Diet followed by Modified Intermittent Fasting
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- University Hospital, Ghent
Psoriasis Vulgaris
A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method…
- Trial name
- NCT01580488
- Testing
- B LEO 35299 20 mg/g cream, C LEO 35299 20 mg/g cream, E LEO 35299 10 mg/g solution
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Psoriasis, Metabolic Syndrome
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
This study was a randomized, open-label, parallel-group, active comparator controlled study with two treatment arms designed to answer the question whether the combination of Secukinumab with lifestyle intervention could…
- Trial name
- METABOLYX (NCT03440736)
- Testing
- Secukinumab, Life-style intervention
- Where
- 75 sites in Germany
- Volunteers
- 781 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris.
- Trial name
- NCT00050648
- Testing
- Daclizumab, Cyclosporine, cyclosporine and Daclizumab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
Psoriasis
Bexarotene With Narrow-Band UVB for Psoriasis
To determine if bexarotene gel with NBUVB phototherapy is more effective than placebo plus NBUVB for moderate to severe plaque-type psoriasis.
- Trial name
- NCT00151008
- Volunteers
- 35 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Psoriasis Vulgaris
Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis
This was a retrospective, observational study. The objective of the study is investigate the efficacy and safety of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
- Trial name
- NCT03828643
- Testing
- Secukinumab
- Where
- Italy
- Volunteers
- 156 people
- Sponsor
- Universita di Verona
Psoriasis Vulgaris
Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin
Changes in microbiome have been reported recently in psoriasis lesions compared to healthy surround skin. Preliminary data showed that systemic treatments of psoriasis induce modification of the skin microbiome that becomes…
- Trial name
- Microbiome&Pso (NCT03584360)
- Testing
- Betamethasone-Calcipotriene Topical
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris
Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2.
- Trial name
- NCT00216892
- Testing
- Calcipotriol, (calcipotriol + betamethasone)
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 1,032 people
- Sponsor
- LEO Pharma
Psoriasis, Atopic Dermatitis
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied.
- Conditions
- Psoriasis, Atopic Dermatitis, Acne
- Trial name
- NCT04633616
- Testing
- Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Chronic Plaque-type Psoriasis
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic…
- Trial name
- ARROW (NCT03553823)
- Testing
- Skin biopsies
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01241591
- Testing
- CP 690,550 5 mg, CP 690,550 10 mg, Etanercept 50 mg
- Where
- 122 sites in Argentina, Austria and 24 more
- Volunteers
- 1,101 people
- Sponsor
- Pfizer
Psoriasis Vulgaris, Inflammation
The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesions
Psoriasis vulgaris is a chronic inflammatory skin disease mediated by the immune system, with a complex pathogenesis that requires long-term therapy.
- Trial name
- NCT06887322
- Testing
- Ciplukan, Bethametasone valerate 0,1% cream
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Padjadjaran
Psoriasis Vulgaris
Ultraviolet Radiation Forecasting Based Heliotherapy For Psoriasis in Bangkok, Thailand
Due to limited number of phototherapy centres and shortage of qualified phototherapy practitioners, heliotherapy has become a promising treatment alternative in Thailand where patients effortlessly receive supervised sun-bathing…
- Trial name
- NCT04740983
- Testing
- Heliotherapy (a sole sun-bathing)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L